CL2008002479A1 - Pharmaceutical composition comprising: a) one or more drug substances, b) a lipid, c) a co-lipid and d) a flow improver; dry powder formulation; manufacturing processes. - Google Patents

Pharmaceutical composition comprising: a) one or more drug substances, b) a lipid, c) a co-lipid and d) a flow improver; dry powder formulation; manufacturing processes.

Info

Publication number
CL2008002479A1
CL2008002479A1 CL2008002479A CL2008002479A CL2008002479A1 CL 2008002479 A1 CL2008002479 A1 CL 2008002479A1 CL 2008002479 A CL2008002479 A CL 2008002479A CL 2008002479 A CL2008002479 A CL 2008002479A CL 2008002479 A1 CL2008002479 A1 CL 2008002479A1
Authority
CL
Chile
Prior art keywords
lipid
pharmaceutical composition
dry powder
powder formulation
manufacturing processes
Prior art date
Application number
CL2008002479A
Other languages
Spanish (es)
Inventor
Fadi Eskandar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40149638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008002479A1 publication Critical patent/CL2008002479A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Abstract

Composición farmacéutica que comprende una o más drogas, un lípido, un co-lípido y un mejorador de flujo, donde dichos elementos juntos forman una dispersión liposomal, una formulación en polvo seco y proceso para preparar una composición farmacéutica.Pharmaceutical composition comprising one or more drugs, a lipid, a co-lipid and a flow enhancer, where said elements together form a liposomal dispersion, a dry powder formulation and a process for preparing a pharmaceutical composition.

CL2008002479A 2007-08-24 2008-08-22 Pharmaceutical composition comprising: a) one or more drug substances, b) a lipid, c) a co-lipid and d) a flow improver; dry powder formulation; manufacturing processes. CL2008002479A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114981 2007-08-24
EP07123163 2007-12-13

Publications (1)

Publication Number Publication Date
CL2008002479A1 true CL2008002479A1 (en) 2009-05-08

Family

ID=40149638

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002479A CL2008002479A1 (en) 2007-08-24 2008-08-22 Pharmaceutical composition comprising: a) one or more drug substances, b) a lipid, c) a co-lipid and d) a flow improver; dry powder formulation; manufacturing processes.

Country Status (5)

Country Link
AR (1) AR067997A1 (en)
CL (1) CL2008002479A1 (en)
PE (1) PE20090607A1 (en)
TW (1) TW200916126A (en)
WO (1) WO2009027337A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN00380A (en) 2006-06-30 2015-06-19 Iceutica Pty Ltd
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
SG10201607288VA (en) 2012-05-03 2016-10-28 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
WO2018160295A1 (en) * 2017-01-25 2018-09-07 Yiannios James John Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
AU2019215127A1 (en) 2018-02-01 2020-06-18 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
US20190231783A1 (en) * 2018-02-01 2019-08-01 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
MX2021005508A (en) * 2018-11-13 2021-09-08 Civitas Therapeutics Inc Respirable polynucleotide powder formulations for inhalation.
US20220249678A1 (en) * 2019-07-10 2022-08-11 The University Of Hong Kong PEGylated synthetic KL4 peptide, Compositions and Methods Thereof
CN114209651A (en) * 2021-11-18 2022-03-22 上海欣峰制药有限公司 Pharmaceutical preparation of cefotaxime sodium compound and preparation method thereof
CN114053226A (en) * 2021-11-18 2022-02-18 上海欣峰制药有限公司 Pharmaceutical preparation of cefminox sodium compound and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004787A1 (en) * 1995-08-01 1997-02-13 Novartis Ag Liposomal oligonucleotide compositions
EP2666858A1 (en) * 2003-04-17 2013-11-27 Alnylam Pharmaceuticals Inc. Modified iRNA agents
JPWO2005011632A1 (en) * 2003-08-01 2006-09-14 独立行政法人産業技術総合研究所 Target-directed and intestinal absorption-controllable liposomes having sugar chains and cancer therapeutics and diagnostics containing the same
CA2565633C (en) * 2004-05-05 2016-04-26 Atugen Ag Lipids, lipid complexes and use thereof
GB0418172D0 (en) * 2004-08-13 2004-09-15 Ic Vec Ltd Vector
CN101111269A (en) * 2005-01-28 2008-01-23 协和发酵工业株式会社 Composition for inhibiting expression of target gene
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
US20090074852A1 (en) * 2006-04-20 2009-03-19 Silence Therapeutics Ag Lipoplex formulations for specific delivery to vascular endothelium
GB0608838D0 (en) * 2006-05-04 2006-06-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2009027337A1 (en) 2009-03-05
TW200916126A (en) 2009-04-16
PE20090607A1 (en) 2009-06-11
AR067997A1 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
CL2008002479A1 (en) Pharmaceutical composition comprising: a) one or more drug substances, b) a lipid, c) a co-lipid and d) a flow improver; dry powder formulation; manufacturing processes.
AR114143A2 (en) COATED TABLET FORMULATIONS
CR11740A (en) COMPOSITIONS THAT INCLUDE SLIGHTLY BASIC DRUGS AND CONTROLLED RELEASE DOSAGE FORMS
CY1119798T1 (en) FORM IV IV Hydrochloride Ibabradine
UY31879A (en) PHARMACEUTICAL DOSAGE FORM IN CAPSULE THAT INCLUDES A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
FR2949062B1 (en) NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES
BRPI0814666A2 (en) pharmaceutical composition for oral administration, use of a formulation. process for preparing a solid dosage form, and, solid dosage form
UY31867A (en) NEW SOLID PHARMACEUTICAL FORMULATIONS THAT INCLUDE BIBW 2992
UY29701A1 (en) LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
DK2178881T3 (en) HIS UNKNOWN 6-TRIAZOLOPYRIDAZINE-SULFANYL-BENZOTHIAZOL AND -BENZIMIDAZOLD DERIVATIVES, PROCEDURES FOR PREPARING THEREOF, USING ITS LIKE PHARMACEUTICALS AND PHARMACEUTICALS AND SAME MEDICINES AND SAME MEDICINALS
CL2008003366A1 (en) Compounds derived from fused nitrogen heterocycles, mek and mapk / erk protein kinase inhibitors; compound preparation process; pharmaceutical composition comprising them; set that includes them; and its use in the preparation of medicaments for the treatment of hyperproliferative disorders.
AR054511A1 (en) A COMPOSITION THAT INCLUDES EMTRICITABINE AND TENOFOVIR DRY GRANULATES
UY31456A1 (en) DERIVATIVES OF 2-PIRAZINONA AS INHIBITORS OF THE ELASTASA DE LOS NEUTROFILOS
WO2009074351A3 (en) Solid forms of tenofovir disoproxil
LTPA2019508I1 (en) Drug delivery system for the delivery of hard-water-soluble, pharmaceutically active substances
UY30308A1 (en) MGLUR5 V MODULATORS
EA201001857A1 (en) PHARMACEUTICAL MEDICINE FORM FOR IMMEDIATE RELEASE OF INDOLINON DERIVATIVE
CL2012002909A1 (en) Process for preparing a pharmaceutical composition comprising a) a granulated center consisting of agglomerated active ingredient grains in the presence of binder and b) a coating layer of said granulated center constituted by fatty matrix; pharmaceutical composition; and its use for oral administration
BRPI0615195A8 (en) pharmaceutical preparation, packaging, and methods for treating gastrointestinal disease, for manufacturing a capsule and for testing dissolution of balsalazide capsules.
CR20150266A (en) MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
BR112018077541A2 (en) gastro-retentive oral formulations and uses thereof
CO6640305A2 (en) Preparation of granules without active ingredients and tablets comprising them
WO2010127205A3 (en) Fixed dose drug combination formulations
BRPI0607413A2 (en) pharmaceutical composition comprising indolylmaleimide derivatives